Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis Alan MenterTina BhutaniAbby Jacobson Review Open access 07 June 2022 Pages: 1289 - 1302
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis Francesco BellinatoPaolo GisondiGiampiero Girolomoni Original Research Open access 27 April 2022 Pages: 1303 - 1311
Minimally Invasive Skin Transcriptome Extraction Using a Dermal Biomarker Patch Sherrif F. IbrahimBradford J. TaftTobin J. Dickerson Original Research Open access 30 April 2022 Pages: 1313 - 1323
Efficacy and Safety of Using Noninsulated Microneedle Radiofrequency Alone Versus in Combination with Polynucleotides for the Treatment of Melasma: A Pilot Study Ma. Christina B. GulfanRungsima WanitphakdeedechaSarawalai Rakchart Original Research Open access 11 May 2022 Pages: 1325 - 1336
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset Lawrence F. EichenfieldApril ArmstrongUsha G. Mallya Original Research Open access 11 May 2022 Pages: 1337 - 1350
Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting Bruce StroberDhaval PatilMark Lebwohl Original Research Open access 13 May 2022 Pages: 1351 - 1365
Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP) A. David BurdenUlrich MrowietzAlan Menter Original Research Open access 19 May 2022 Pages: 1367 - 1381
Desire for Alternative Treatment Options in Patients with Atopic Dermatitis in Japan: Results of a Web-Based Cross-Sectional Study (AD-JOIN Study) Takeshi NakaharaShunya TakemotoMasahiko Nakayama Original Research Open access 18 May 2022 Pages: 1383 - 1396
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results Yukari OkuboYoshinori UmezawaHidemi Nakagawa Original Research Open access 27 May 2022 Pages: 1397 - 1415
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE) Jerry BagelTien Q. NguyenMarius Ardeleanu Original Research Open access 20 May 2022 Pages: 1417 - 1430
Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure Christopher E. M. GriffithsMelinda GooderhamAndrew Blauvelt Original Research Open access 27 May 2022 Pages: 1431 - 1446
Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults Lida TengAkiko MizukamiTaizo Matsuki Original Research Open access 06 June 2022 Pages: 1447 - 1467
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study Yukari OkuboHidetoshi TakahashiMasatoshi Abe Original Research Open access 11 June 2022 Pages: 1469 - 1480
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Marjolein S. de Bruin-WellerEsther Serra-BaldrichThomas Werfel Brief Report Open access 11 May 2022 Pages: 1481 - 1491
The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China Yue XiaoHui ChenWei Li Brief Report Open access 26 May 2022 Pages: 1493 - 1500